Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice
BioMed Research International · 2026
DOI: 10.1155/bmri/5630909 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2026. Verfasst von Qing Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China, …. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Gastrointestinal Microbiome, Abelmoschus, Plant Extracts. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhong Pharmaceutical Group Co. Ltd.
Abstract (Originalsprache)
Background
Huangkui capsule (HKC), derived from the ethanol extract of Abelmoschus manihot (L.) flowers, is widely used in China for treating kidney diseases, including diabetic nephropathy (DN). Our previous study demonstrated that HKC modulates the intestinal microbiota and circulating metabolites in non‐obese diabetic mice, a type 1 diabetes model. To further explore its efficacy, we evaluated HKC in db/db mice, a well‐established type 2 diabetes and DN model.
Methods
An HKC cohort studied in 2022 was compared with historical Ctrl and DN cohorts studied in 2021. Shotgun metagenomic sequencing was performed to characterize intestinal microbiota changes, while liquid chromatography–mass spectrometry (LC–MS)‐based plasma metabolomics was used to identify alterations in circulating metabolites. The biological functions of the altered microbiota and plasma metabolites were analyzed, and the potential association between the intestinal microbiome and plasma metabolome was evaluated.
Results
Compared with the historical DN cohort, the HKC cohort had higher abundances of Streptococcaceae , Streptococcus , and Massilimaliae and lower abundances of Alloprevotella and Prevotellamassilia in exploratory comparisons. In the HKC‐versus‐DN comparison, the archived gene set enrichment analysis reported 15 pathways with nominal positive enrichment. Additionally, 12 plasma metabolites were upregulated and 14 downregulated, including branched‐chain amino acids (DL‐leucine, DL‐valine, D‐isoleucine), organic acids (N‐methyl‐ α ‐aminoisobutyric acid, guanidineacetic acid), and choline.
Conclusion
In db/db mice, the cohort receiving A. manihot (L.)‐derived HKC had lower urinary albumin‐to‐creatinine ratio (UACR) and different intestinal microbiota and plasma metabolite profiles than the historical DN cohort, highlighting its therapeutic potential for DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China, cpu.edu.cn.
ORCID-Profile: Qing Xu, Yuhui Song, Hongmei Yu, Harvest F Gu
Förderung
- Suzhong Pharmaceutical Group Co. Ltd
Zitieren
APA
Xu, Q., Song, Y., Yu, H., Wang, Y., & Gu, H. F. (2026). Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice. BioMed Research International. https://doi.org/10.1155/bmri/5630909
Vancouver
Xu Q, Song Y, Yu H, Wang Y, Gu HF. Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice. BioMed Research International. 2026. doi:10.1155/bmri/5630909
BibTeX
@article{Xu2026,
author = {Xu, Qing and Song, Yuhui and Yu, Hongmei and Wang, Yurong and Gu, Harvest F},
title = {Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice},
journal = {BioMed Research International},
year = {2026},
doi = {10.1155/bmri/5630909}
}
EUVIMED